Skip to content

Trial Summary

BGB-A425 is a humanized, immunoglobulin gamma-1 (IgG1)-variant monoclonal antibody against TIM-3. Tislelizumab is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against PD-1. This study tests the safety and anti-tumor effect of BGB-A425 in combination with tislelizumab in participants with advanced solid tumors.



ACTRN/NCT /ethics:


Scientific title:

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeAll cancers; Lung & mesothelioma; Head & neck
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18+ years
Tumour Stream-
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2018-11-13
Anticipated End Date2024-01-01

Participating Hospitals

HospitalCalvary North Adelaide Hospital
Clinical Trial CoordinatorJulie Rowe
Phone08 8239 9536
Principal InvestigatorDr Vy Broadbridge
Recruitment StatusRecruiting